The biotech is on track to hit its 2019 revenue guidance for Adceris sales to increase 28% to 34%.
News & Analysis: Seattle Genetics
SGEN earnings call for the period ending March 31, 2019.
Earnings took down some key companies today.
With shares up 30% year to date, investors may be taking profits.
SGEN earnings call for the period ending December 31, 2018.
Front-line Hodgkin lymphoma turns out to be a tough market to crack.
Third-quarter earnings weren't what investors (or management) were hoping for.
SGEN earnings call for the period ending September 30, 2018.
Frontline treatment of Hodgkin lymphoma drives Adcetris sales to new heights.
An expanded approval has doctors prescribing the biotech's blood cancer drug, Adcertis, to more patients.